Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Discipline in budgeting supports steady progress toward financial goals. Use clear rules, regular reviews, and accountability to stay on track.
22,770 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Investors are weighing how legal rulings against Meta could reshape risk and earnings. This guide breaks down what ha...
Geopolitical tensions push yields higher, nudging mortgage rates tick higher and complicating spring homebuying for m...
Aave asks a New York court to lift a restraining order on ETH set aside for victims of a DeFi breach, arguing the ass...
Discover how to spot cash-flow opportunities in Zillow’s ranked market ripe. This guide breaks down how to evaluate d...
Stocks trim gains as a risk-on mood cools. The Nasdaq Composite weakens, while tech names temper their rally as trade...
The stock market is rallying, but the financial sector has lagged, a sign of narrow breadth that could portend bigger...
Ripple Chief Brad Garlinghouse floated the idea of a potential perk for XRP holders if Ripple ever goes public, while...
Crypto traders are weighing ripple (xrp) solana (sol) as summer enters. The rivals push higher, but investors cite di...
A new wave of fiber-infused sodas and gummies is hitting shelves as 'fibermaxxing' spurred a fiber push across snacks...
Choosing between IXUS and VYMI can shape your international exposure. This guide breaks down what each fund holds, co...
Artificial intelligence quarterly earnings are changing how investors digest company reports. This guide explains the...